Research

Adicet reports early lupus results for off-the-shelf CAR-T therapy

Endpoints News reported symptom improvement in Adicet’s early lupus study of prula-cel, an off-the-shelf CAR-T therapy.

Reported by 2 outlets Tuesday, September 29, 2026

Bacterial colonies growing in a petri dish — Photo: CC0

Adicet reported early results for prula-cel, an off-the-shelf CAR-T therapy being tested in lupus. The treatment is made from donor cells and uses gamma delta T cells. Endpoints News reported that the therapy improved symptoms in the early-stage study.

BioPharma Dive said the efficacy data were competitive with cell therapies and antibodies, and cited peer cell therapy makers’ complete response rates of about 40%. About a quarter of prula-cel patients experienced mild or moderate CRS. Infections were reported in more than half, and around 8% had infections graded 3 or higher.

Reporting on this story

BioPharma Dive An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus (opens in a new tab)

More top stories

Recalls

Sierra Nevada recalls raw milk cheeses after E. coli outbreak sickens 13

Do not eat any recalled Graziers Raw Milk Cheese, discard it or return it to the place of purchase.

Reported by 4 outlets

Drugs and FDA

FDA approves AbbVie’s Juvmo for adults with Parkinson’s disease

Juvmo is an oral treatment approved for adults with Parkinson’s disease, taken once daily with or without levodopa.

Reported by 3 outlets

Drugs and FDA

Kodiak reports two wet AMD drugs met Phase 3 vision goals

Both experimental drugs were noninferior to Eylea on vision after one year, and Kodiak said 54% of Zenkuda patients went six months between shots.

Reported by 4 outlets